Fritextsökning
Artiklar per år
Innehållstyper
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindgren paints a partly different picture in a new book about the French master's life, health and attitude towards physicians.
-
Ännu ett globalt bolag flyttar till Forskaren
Analys- och kontraktsforskningsföretaget Iqvia flyttar in i Forskaren i Hagastaden, som därmed uppges vara fullt uthyrd.
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks approved treatment alternatives. "We can't do that on our own – our entire R&D activities are about working together with others," says the company's CEO Jens Lindberg.
-
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
Japansk läkemedelsjätte flyttar till Forskaren
Ännu ett stort läkemedelsbolag flyttar in i Forskaren i Hagastaden.
-
Astra Zenecas Kinachef under utredning
Astra Zenecas Kinachef Leon Wang är föremål för utredning av de kinesiska myndigheterna, meddelar företaget. Beskedet fick företagets aktie att dala på börsen.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming
-
Åsa Uppströmer ny vd för Pharma Relations
Pharma Relations har anställt Åsa Uppströmer som ny vd.
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the decision to create a joint profile for the two cities is strongly supported. He mentions that around 50 stakeholders were asked last winter if they were in favour of a joint cluster and that “the answer was a resounding yes”.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
Så blir svenska paviljongen vid Bio-Europe
Jättekonferensen Bio-Europe med över 5 000 deltagare äger i år för första gången rum i Stockholm – och svensk life science samlar styrkorna.
-
Leo Pharma to cut 200 jobs and reorganize
Danish Leo Pharma cuts down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.
-
GSK pays 2.2 billion dollars to settle Zantac lawsuits
British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against the company in the U.S. that alleged its discontinued drug Zantac caused cancer.
-
Leo Pharma omorganiserar och kapar 200 tjänster
Danska Leo Pharma drar ned på personal i sin globala verksamhet. Runt 200 tjänster försvinner medan 50 flyttas till Polen.
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
Umeåbolag rekryterar ny vd
Umeåbolaget Quretech Bio, som utvecklar nya antibiotika och infektionsbehandlingar, har utsett Markus Thor till ny vd.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided to apply for delisting of the company´s share from Nasdaq Stockholm.
-
Sahlgrenska Science Park och UC Berkeley ingår partnerskap – ska hjälpa deeptech-bolag
Sahlgrenska Science Parks accelerator Co-Ax har ingått ett samarbete med UC Berkeleys innovationslabb för deeptech. Syftet med partnerskapet är att accelerera tillväxten av deeptech-bolag i Sverige och Norden.
-
Stor kongress om framtidsutsikter igång i Lund
Vad sker i framtiden inom svensk och dansk life science? Det diskuteras i dag vid eventet The Future of Swedish and Danish Life Science i Lund.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.
-
Ny vd tar över Biotage
Uppsalabaserade Biotage har utsett Frederic Vanderhaegen till ny vd. Han tillträder den 16 september och efterträder då Torben Torben Jørgensen, som återgår till att vara styrelseledamot.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
BREAKING